2021
DOI: 10.2147/cmar.s341062
|View full text |Cite
|
Sign up to set email alerts
|

Long Noncoding RNA SNHG16 Silencing Inhibits the Aggressiveness of Gastric Cancer via Upregulation of microRNA-628-3p and Consequent Decrease of NRP1 [Retraction]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
3
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 0 publications
0
3
1
Order By: Relevance
“…e TIDE algorithm analysis showed that patients in the subtype 1 group showed considerably higher TIDE ratings than those in the subtype 2 group, indicating that patients in the subtype 2 group might respond better to immunotherapy. Other noncoding RNAs might be valuable in the prediction of the prognosis of glioma [45][46][47].…”
Section: Discussionmentioning
confidence: 99%
“…e TIDE algorithm analysis showed that patients in the subtype 1 group showed considerably higher TIDE ratings than those in the subtype 2 group, indicating that patients in the subtype 2 group might respond better to immunotherapy. Other noncoding RNAs might be valuable in the prediction of the prognosis of glioma [45][46][47].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, silencing SNHG16 effectively sensitized 5-Fu-resistant GC cells. Although previous studies have reported that SNHG16 was a gastric cancer cell-favorite molecule [31][32][33], our results for the first time demonstrated the roles of SNHG16 in 5-Fu-resistant gastric cancer. Given that lncRNAs function as competitive endogenous RNAs (ceRNA) of miRNAs by sponging them to suppress miRNA expressions, leading to recovery of the miRNA target gene expressions, to investigate the molecular mechanisms, we identified miR-506-3p, which has been reported to function as a tumor suppressive miRNA in multiple cancers [28][29][30], was a directly downstream target of SNHG16 in GC cells by luciferase assay.…”
Section: Discussioncontrasting
confidence: 60%
“…Hence, patients had stable blood levels after daily oral low-dose apatinib with better efficacy than bevacizumab used alone once every 3 weeks. Apatinib not only inhibits tumor neovascularization [23] and suppresses glioma cell invasion but also may activate the GBM immune response to exert antitumor effects [24][25][26][27][28][29]. Common adverse effects of apatinib include hypertension, proteinuria, and hand-foot syndrome, most of which can be tolerated and some of which are controlled by adjusting antihypertensive medications.…”
Section: Discussionmentioning
confidence: 99%